CASE REPORT

Levofloxacin-associated Encephalopathy with Severe Hyperventilation

Mieko Sugiura, Koichi Shibata, Satoshi Saito, Yoshiko Nishimura and Hiroshi Sakura

Abstract:
A 64-year-old woman with no previous mental illness took a single 500 mg tablet of levofloxacin for cystitis. Two hours later, she developed psychosis with involuntary movement and severe hyperventilation with respiratory alkalosis. Cranial magnetic resonance imaging findings were unremarkable, and an electroencephalogram revealed no epileptiform discharge. Her symptoms improved on the third day after levofloxacin was discontinued. Levofloxacin-associated encephalopathy with psychotic features is a rare adverse event. Disturbance of GABAergic interneurons by levofloxacin may lead to hyperventilation via dysfunction of the brainstem respiratory network. Physicians should be aware of hyperventilation as an additional serious symptom of levofloxacin-associated encephalopathy in acute settings.

Key words: levofloxacin, psychosis, antibiotic-associated encephalopathy, central nervous system toxicity, hyperventilation

(Intern Med Advance Publication)
(DOI: 10.2169/internalmedicine.1619-18)

Introduction

Levofloxacin, which is the active isomer of ofloxacin, is a third-generation fluoroquinolone antibiotic that has a broad antibacterial spectrum and is widely used. Pooled safety data for levofloxacin (n=7,537) suggest that the most common adverse drug reactions leading to discontinuation of the medication are gastrointestinal adverse reactions (1.4%), nausea (0.6%), vomiting (0.4%), dizziness (0.3%), and headache (0.2%) (1). The safety and efficacy of levofloxacin have been well documented, and central nervous system (CNS) toxicity is low, occurring in just 1 out of every 6 million prescriptions (2, 3).

We herein report a case of acute psychotic symptoms with severe hyperventilation after a patient took one tablet of levofloxacin. This is the first report describing hyperventilation as an adverse effect of quinolones.

Case Report

A 64-year-old woman had increased urinary frequency and experienced an uncomfortable feeling while urinating for several days. A urologist diagnosed her with cystitis and prescribed levofloxacin. Two hours after taking a single 500 mg tablet of levofloxacin without any other medicine, the patient became restless and confused. She visited the clinic again and was referred to our hospital for a further examination and treatment.

The patient had undergone mastectomy for right breast cancer and received chemotherapy seven years earlier. She had been subsequently followed up with no signs of recurrence. She had no history of a confusional state and no documented disorders of the central nervous system. She was a non-smoker and did not have any history of alcohol misuse or antipsychotic drug use.

On a physical examination, the patient’s temperature was 37.8 °C, and she had a blood pressure of 115/56 mmHg, a heart rate of 114 beats per min, and a respiratory rate of 34 breaths per min. She was confused and disoriented and was becoming agitated. We observed bilateral mild muscular rigidity in the upper and lower limbs and involuntary movement characterized by dyskinesia. She had no episodes of autonomic instability such as hyperhidrosis or convulsions. The patient reported visual hallucinations, saying “a baby boy is lying next to me” and repeating many times that “he
is going to die”.

Laboratory examinations determined a white blood cell count of 8,300/μL, hematocrit of 32.6%, platelet count of 30.7×10^4/μL, serum creatinine level of 0.85 mg/dL, blood urea nitrogen (BUN) level of 16.4 mg/dL, sodium level of 140 mEq/L, potassium level of 2.7 mEq/L, aspartate transaminase level of 53 U/L, alanine aminotransferase level of 42 U/L, lactate dehydrogenase level of 275 U/L, C-reactive protein level of 20.1 mg/dL, thyroid stimulating hormone level of 2.66 μIU/mL, and NH3 level of 20 μg/dL. An assessment of the patient’s blood gas revealed a pH of 7.82, pCO2 of 10.3 mmHg, pO2 of 165 mmHg, and HCO3 of 17.6 mmol/L. Anti NMDA receptor antibody was not detected. Chest X-ray showed no active lesions, and head computed tomography (CT) and brain magnetic resonance imaging (MRI) showed no abnormal findings. Whole-body CT and MRI to assess the abdomen and pelvis revealed no active or tumorous lesions. A cerebrospinal fluid (CSF) analysis provided a white cell count of 1 cell/μL, with glucose and protein levels of 66 mmol/L and 14.2 g/L, respectively. An electroencephalogram (EEG) on the second day showed intermittent rhythmic delta activity with background beta activity but no epileptiform discharge (Figure).

The patient presented with hyperventilation with a respiratory rate of approximately 90 breaths per min and exacerbation of severe respiratory alkalosis. Her hyperventilation improved gradually on the third day of admission following the injection of 10 mg haloperidol in addition to 10 mg diazepam.

At admission, after the patient discontinued levofloxacin, meningoencephalitis was suspected, so she was treated with antibiotic medication (vancomycin, ceftriaxone, ampicillin, and acyclovir). On the fourth day, she was able to say her name but remained drowsy and showed coarse tremor in all her limbs. Since these symptoms were improving, medication was stopped on the fourth day of admission. On the fifth day, the patient became mostly alert and oriented but still had impaired attention, with a Mini-Mental State Examination score of 25. She was discharged after 17 days without any neurological deficits.

**Discussion**

Although medications are commonly considered a reversible cause of encephalopathy, antibiotics are underrecognized in the etiology of the condition. In this case, the temporal relationship between the patient’s consumption of levofloxacin and the acute alteration in her level of consciousness suggested that levofloxacin was the precipitant of the psychotic symptoms. Bhattacharyya et al. (4) conducted a review and proposed the concept of antibiotic-associated encephalopathy (AAE). They classified AAE into three types, with quinolones belonging to Type 2 AAE, which is characterized more by predominant psychotic symptoms than seizures or myoclonus. AAE arises within days of antibiotic administration and resolves after antibiotic discontinuation. Due to the marked improvement observed on discontinuing levofloxacin in this case, we diagnosed the condition as levofloxacin-associated encephalopathy, and the original cause of the fever was presumably cystitis.

To our knowledge, there have been 12 case reports, including the present one, on levofloxacin-associated encephalopathy (5-15) (Table). The patients ranged in age from 13-83 years (mean, 46 years old). The dose of levofloxacin administered ranged from 300 to 500 mg/day, and all patients showed symptoms of psychosis, while 2 presented with extra pyramidal signs. An EEG was performed in just four patients, with only one patient other than our own showing
Table. Previously Reported Cases of Levofloxacin-associated Encephalopathy.

| Case no. | RN  | Age  | Sex | Underlying disease                          | Reason for prescription | Renal failure | Daily dose | Time to symptom onset | Recovery time after discontinuation | EEG  | MRI/CT | CSF  | Other symptoms                        | Prognosis |
|----------|-----|------|-----|--------------------------------------------|-------------------------|---------------|------------|----------------------|-------------------------------------|-------|---------|------|-----------------------------|-----------|
| 1        | 5   | 67   | M   | Gall bladder cancer and alcohol dependence | Flu                     | N             | 300 g/day p.o. | 4 days               | 1 day                               | ND    | ND      | ND   | Involuntary movements and convulsions | Good      |
| 2        | 6   | 73   | M   | N                  | Pneumonia               | N             | 500 mg/day p.o. | 2 days               | 2 days                               | ND    | No specific finding | ND   | NP                                      | Good      |
| 3        | 7   | 50   | M   | Diabetes mellitus and hypertension          | Pneumonia, UTI and cellulitis | N             | 500 mg/day p.o. | 3 days               | 2 days                               | ND    | ND      | WNL | NP                                      | Good      |
| 4        | 8   | 42   | F   | N                  | Sinusitis and UTI       | N             | 500 mg/day p.o. | 2 days               | 2 days                               | ND    | ND      | WNL | NP                                      | Good      |
| 5        | 9   | 83   | M   | Coronary bypass surgery and breast carcinoma | Pneumonia                | Y             | 500 mg/day IV | 3 days               | 2 days                               | Slow background activity | ND    | WNL     | Extrapylamidal syndrome | Good      |
| 6        | 10  | 55   | M   | Hypertension and inguinal hernia            | Pneumonia                | Y             | 500 mg/day IV | 6 days               | 2 days                               | WNL   | WNL     | ND   | NP                                      | Good      |
| 7        | 11  | 13   | F   | N                  | Acute bronchitis         | N             | 500 mg/day p.o. | 2 h                  | 4 days                               | WNL   | WNL     | WNL | NP                                      | Good      |
| 8        | 12  | 38   | M   | Multiple sclerosis and hepatitis C           | Pneumonia                | N             | 500 mg/day p.o. | 3 days               | 1 day                               | ND    | ND      | ND   | NP                                      | Good      |
| 9        | 13  | 28   | M   | N                  | Pneumonia and UTI        | N             | 500 mg/day p.o. | 3 days               | 2 days                               | ND    | ND      | WNL | NP                                      | Good      |
| 10       | 14  | 17   | M   | Synovial sarcoma with metastasis            | Pneumonia                | ND            | 500 mg/day IV | 35 min               | 4 h                                  | ND    | ND      | ND   | NP                                      | Good      |
| 11       | 15  | 22   | F   | N                  | UTI                     | N             | 500 mg/day p.o. | 3 h                  | 3 days                               | ND    | ND      | ND   | Good                                    | Good      |
| 12       | 64  | F    | Breast cancer                      | Cystitis                | N             | 500 mg/day p.o. | 2 h                  | 4 days                               | Intermittent rhythmic delta activity with background beta activity | WNL   | WNL     | WNL | Hyperventilation, involuntary movement, and rigidity | Good      |

R.N: reference number; M: male; F: female; NP: none present; UTI: urinary tract infection; IV: intravenous; N: no; Y: yes; ND: not described; p.o.: per os; EEG: electroencephalogram; MRI: magnetic resonance imaging; CT: computed tomographic scanning; WNL: within normal limits; CSF: cerebrospinal fluid.
to 2.4 hours after the administration of 50-1,000 mg with or without food (16). Therefore, while the time to the onset of symptoms was shorter in this case than in previously reported cases, that psychosis developed just 2 hours after the oral intake is not unexpected. According to previous reports, the mean age of patients with an acute onset (not including our patient) was 17.3 years, whereas the mean age of the patients with a relatively late onset was 54.5 years. Although the acute development of hyperventilation is more frequent in young patients than in older ones, this might be due to the blood-brain barrier influencing the concentrations of levofloxacin in the brain tissue to a variable degree (17). Additional case reports will be required to confirm the etiology associated with a more acute onset.

Previous studies have suggested that the pathophysiology of levofloxacin-associated encephalopathy is associated with a disturbance of GABAergic interneurons. Quinolones affect the central nervous system mainly by inhibiting GABA receptor binding, which is concentration-dependent (18). Some animal models suggest that the onset of psychosis involves dysfunction of GABAergic interneurons, leading to excessive cortical glutamatergic activity, which in turn mediates subcortical dopamine activity (19).

In the present case, in addition to psychotic features, the patient experienced prominent ventilation disturbance. This is the first report describing hyperventilation as an adverse effect of quinolones. Hyperventilation persisted for approximately 36 hours with respiratory alkalosis, with the pH increasing to 7.82 on blood gas examinations. The major cause of central neurogenic hyperventilation is infiltrative tumors involving the brainstem (20). However, there are a few cases of hyperventilation caused by anti-NMDA receptor encephalitis (21, 22). An antibody-mediated decrease in NMDA receptors predominantly inactivates GABAergic neurons and leads to many clinical features of the disorder (23).

The generation of ventilatory rhythm via the brainstem derives from a complex interplay between several brainstem sites. The NMDA receptor system may play an excitatory role in several steps leading both to the augmentation and termination of inspiration (24). As in cases of anti-NMDA receptor encephalitis, impaired GABAergic interneurons may lead to hyperventilation via dysfunction of the brainstem respiratory network. In addition, other symptoms, including extrapyramidal signs, such as rigidity and dyskinesia, can also be caused by the disinhibition of dopaminergic and glutaminergic neurons arising from the same neuronal network disturbance as in anti-NMDA receptor encephalitis. Both hyper- and hyperventilation can also be explained based on a functional neurotransmitter imbalance which is predominantly characterized by the presence of hypo-GABAergic tone and glutamatergic hyperactivity (23). Therefore, it may be important to identify altered respiratory rhythm patterns in cases of levofloxacin-associated encephalopathy.

Levofloxacin-associated encephalopathy characterized by psychotic features is a rare adverse event that can occur within two hours after taking a single tablet. In addition, the disturbance of GABAergic interneurons by levofloxacin may lead to hyperventilation via dysfunction of the brainstem respiratory network. Physicians should be aware of hyperventilation as an additional serious symptom of AAE in acute settings.

Author’s disclosure of potential Conflicts of Interest (COI).
Sakura H: Honoraria, Sanofi, Mitsubishi Tanabe pharma and Astellas Pharma Inc; Research funding, Takeda, Daiichi Sankyo Company, Ono Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co.,Ltd, Mitsubishi Tanabe pharma, MSD, Eisai Co., Ltd. Novartis, Astellas Pharma Inc. and Novo Nordisk Pharma Ltd.

References
1. Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf 33: 353-369, 2010.
2. Norby SR. Levofloxacin. Expert Opin Pharmacother 1: 109-119, 1999.
3. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy 47: 9-14, 2001.
4. Bhattacharyya S, Darby RR, RaiBagkar P, Gonzalez Castro LN, Berkowitz AL. Antibiotic-associated encephalopathy. Neurology 86: 963-971, 2016.
5. Yasuda H, Yoshida A, Masuda Y, Fukayama M, Kita Y, Inamatsu T. Levofloxacin-induced neurological adverse effects such as, involuntary movement (tremor, myoclonus and chorea like), visual hallucination in two elderly patients. Nihon Ronen Igakkai Zasshi 36: 213-217, 1999 (in Japanese).
6. Hakko E, Mete B, Ozaras R, Tabak F, Ozturk R, Mert A. Levofloxacin-induced delirium. Clin Neurol Neurosurg 107: 158-159, 2005.
7. Moorthy N, Raghavendra N, Venkataraathnamma PN. Levofloxacin-induced acute psychosis. Indian J Psychiatry 50: 57-58, 2008.
8. Kiangkittiwon B, Doppalapudi A, Fonder M, Solberg K, Bohnier B. Levofloxacin induced delirium with psychotic features. Gen Hosp Psychiatry 30: 381-383, 2008.
9. Slobodin G, Elias N, Zaygraikin N, et al. Levofloxacin-induced delirium. Neurol Sci 30: 159-162, 2009.
10. Kochygit I, Dortdudak S, Sipahioglu M, et al. Levofloxacin-induced delirium: is it a dangerous drug in patients with renal dysfunction. Ren Fail 34: 634-636, 2012.
11. Raj V, Murthy TV. Levofloxacin induced delirium with psychotic features in a young patient. Med J Armed Forces India 69: 404-405, 2013.
12. Lertxundi U, Palacios RH, Gutierrez FC, Domingo-Echaburu S, Garcia MG, Gomez CA. Levofloxacin-Induced Delirium in a Patient Suffering from Schizoaffective Disorder and Multiple Sclerosis. Curr Drug Saf 8: 199-200, 2013.
13. Singh D, Kapoor A, Singhal MK, Singh V, Kumar HS. Levofloxacin-induced psychosis: a rare case report. Int J Basic Clin Pharmacol 3: 726-728, 2014.
14. Ghosal A, Damani A, Salins N, Deodhar J, Muckaden MA. Management of levofloxacin induced anaphylaxis and acute delirium in a palliative care setting. Indian J Palliat Care 21: 76-78, 2015.
15. Takser L, Grad R. Acute psychotic symptoms following a single dose of levofloxacin. Clin Case Rep 5: 2136-2137, 2017.
16. North DS, Fish DN, Redington JJ. Levofloxacin, a second-generation fluoroquinolone. Pharmacotherapy 18: 915-935, 1998.
17. Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly. An update. Drugs Aging 27: 193-209, 2010.
18. Hori S, Shimada J. Effects of quinolones on the central nervous system. In: Quinolone Antimicrobial Agents. 2nd ed. Hooper D C, Wolfson J S, Eds. American Society for Microbiology, Washington DC, 1993: 513-518.
19. McGuire P, Allen P, Howes O, et al. GABA interneuron dysfunction and the onset of psychosis. Schizophr Bull 43: S3-S4, 2017.
20. Tarulli AW, Lim C, Bui JD, Saper CB, Alexander MP. Central neurogenic hyperventilation: a case report and discussion of pathophysiology. Arch Neurol 62: 1632-1634, 2005.
21. Vural A, Arsava MA, Dericioglu N, Topcuoglu MA. Central neurogenic hyperventilation in Anti-NMDA receptor encephalitis. Intern Med 51: 2789-2792, 2012.
22. Ikeguchi R, Shibuya K, Akiyama S, et al. Rituximab used successfully in the treatment of Anti-NMDA receptor encephalitis. Intern Med 51: 1585-1589, 2012.
23. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10: 63-74, 2011.
24. Waters KA, Machaalani R. Role of NMDA receptors in development of respiratory control. Respir Physiol Neurobiol 149: 123-130, 2005.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).